Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.2K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.2K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

705
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
705
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

549
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
549
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.3K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma diagnosis in adults and children: challenges, future directions, and a call to action.

The Lancet. Respiratory medicine·2026
Same author

Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin.

The European respiratory journal·2026
Same author

Ventilator Control Variables: Pressure Control, Volume Control, and Adaptive Targeting of Pressure Control.

NeoReviews·2026
Same author

Assessing the reliability of upper airway sampling for microbiological surveillance in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial.

The European respiratory journal·2025
Same author

Reply to Zeng: the SOOTHE trial of camlipixant in RCC: a cautionary note on stratification and relevance.

American journal of respiratory and critical care medicine·2025

Related Experiment Video

Updated: Jan 22, 2026

Methods for Detecting Cough and Airway Inflammation in Mice
04:33

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

1.1K

Cough: New Pharmacology.

Jaclyn A Smith1, Huda Badri2

  • 1Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; Division of Infection, Immunity, and Respiratory Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

The Journal of Allergy and Clinical Immunology. in Practice
|July 8, 2019
PubMed
Summary
This summary is machine-generated.

New P2X3 antagonists show promise for treating refractory chronic cough, a condition with limited options. Further research into cough mechanisms is crucial for developing targeted therapies for better patient outcomes.

Keywords:
Airway nervesAntitussiveCough monitoringNeuromodulators

More Related Videos

Precision Induction and Distinction of Coughing and Sneezing Reflexes in Mice
09:30

Precision Induction and Distinction of Coughing and Sneezing Reflexes in Mice

Published on: October 3, 2025

1.2K
Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
05:43

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

1.2K

Related Experiment Videos

Last Updated: Jan 22, 2026

Methods for Detecting Cough and Airway Inflammation in Mice
04:33

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

1.1K
Precision Induction and Distinction of Coughing and Sneezing Reflexes in Mice
09:30

Precision Induction and Distinction of Coughing and Sneezing Reflexes in Mice

Published on: October 3, 2025

1.2K
Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
05:43

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

1.2K

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Neuroscience

Background:

  • Chronic cough significantly impairs quality of life.
  • Current licensed therapies for chronic cough are limited.
  • Refractory chronic cough lacks effective treatment options.

Purpose of the Study:

  • To review novel therapies for chronic cough.
  • To summarize treatments targeting the peripheral and central nervous systems.
  • To discuss the development of new therapeutic approaches.

Main Methods:

  • Literature review of recent developments in chronic cough therapies.
  • Analysis of P2X3 antagonists and other novel drug targets.
  • Examination of pathophysiological mechanisms of cough.

Main Results:

  • P2X3 antagonists demonstrate efficacy in refractory chronic cough.
  • Interest in novel therapies for chronic cough has increased.
  • Research is expanding to include common respiratory diseases.

Conclusions:

  • Novel therapies, particularly P2X3 antagonists, offer hope for chronic cough.
  • Understanding cough pathophysiology is key to identifying drug targets.
  • Personalized treatment approaches are needed for optimal patient management.